Prime Medicine ($PRME) Stock Forecast: Up 5.9% Today

What is Prime Medicine?

Prime Medicine (PRME.US) is a biotechnology company listed on the NasdaqGM. The company focuses on gene-editing technologies to develop treatments for various genetic disorders, with a current emphasis on liver diseases like Wilson's Disease and Alpha-1 Antitrypsin Deficiency.

Why is Prime Medicine going up?

PRME stock is up 5.9% on May 11, 2026 14:25

• Despite reporting a Q1 loss and missing revenue estimates, Prime Medicine (PRME) experienced a bullish market movement today.
• The bullish trend could be attributed to the company's strategic initiatives, such as appointing new executives, initiating equity offerings, and prioritizing its liver disease programs.
• Analysts forecasting significant revenue growth and a higher price target for PRME might have also contributed to the positive market sentiment.
• Investors seem optimistic about Prime Medicine's gene-editing pipeline progress, promising preclinical data, and ongoing regulatory efforts, leading to the bullish movement in the stock.

PRME Price Chart

PRME Technical Analysis

PRME News

H.C. Wainwright Maintains Prime Medicine(PRME.US) With Hold Rating

H.C. Wainwright has reiterated its Hold rating on Prime Medicine (PRME.US). This indicates that the firm advises investors to maintain their current positions in the company's stock, suggesting a neutral outlook on its near-term performance.

https://www.moomoo.com/news/post/69655414/hc-wainwright-maintains-prime-medicine-prmeus-with-hold-rating

Prime Medicine (NasdaqGM:PRME) Stock Forecast & Analyst Predictions

Prime Medicine (NasdaqGM:PRME) is forecast to experience declining earnings but significant revenue growth, with analysts predicting a future net loss per share but a higher price target. The company recently appointed new executives and initiated several follow-on equity offerings, while strategically prioritizing its in vivo liver franchise for Wilson's Disease and Alpha-1 Antitrypsin Deficiency. Despite high cash burn and stock volatility, Prime Medicine continues to advance its gene-editing pipeline with promising preclinical data and strategic partnerships.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prme/prime-medicine/future

Prime Medicine, Inc. (PRME) reports Q1 loss, misses revenue estimates

Prime Medicine, Inc. (PRME) reported a Q1 loss, missing revenue estimates. The company's financial performance for the first quarter did not meet analysts' expectations.

https://www.msn.com/en-us/money/topstocks/prime-medicine-inc-prme-reports-q1-loss-misses-revenue-estimates/ar-AA22D1PE

Prime Medicine targets 2 liver disease filings in 2026, data due 2027

Prime Medicine reported Q1 2026 financial results, including a net loss of $49.1 million and a cash position of $149.2 million providing runway into 2027. The company is on track to file IND/CTA applications for its Wilson Disease (PM577) and AATD (PM647) programs in 2026, with initial clinical data from both expected in 2027. Additionally, Prime Medicine continues regulatory dialogue for a potential Biologics License Application (BLA) for PM359 in Chronic Granulomatous Disease (CGD).

https://www.stocktitan.net/news/PRME/prime-medicine-reports-first-quarter-2026-financial-results-and-7kp98535jq5y.html

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine, Inc. reported its first-quarter 2026 financial results, highlighting progress in its Prime Editing platform. The company is on track to file regulatory applications for PM577 in Wilson Disease and PM647 in AATD in mid-2026, with initial clinical data expected in 2027. Additionally, Prime Medicine continues regulatory dialogue for a potential Biologics License Application (BLA) for PM359 in Chronic Granulomatous Disease (CGD) and announced a cash runway into 2027 based on its current financial position.

https://www.manilatimes.net/2026/05/07/tmt-newswire/globenewswire/prime-medicine-reports-first-quarter-2026-financial-results-and-provides-business-updates/2338342

Trending Today

Wheat ($WHEAT) Commodity Forecast: Up 6.3% Today

SBA Communications Corporation ($SBAC) Stock Forecast: Down 1.8% Today

Zebra Technologies Corporation ($ZBRA) Stock Forecast: Up 10.6% Today

Corning Incorporated ($GLW) Stock Forecast: Down 5.1% Today

Huntington Ingalls Industries Inc. ($HII) Stock Forecast: Up 5.1% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 5.0% Today

Opendoor Technologies Inc. ($OPEN) Stock Forecast: Down 5.6% Today

Centene Corporation ($CNC) Stock Forecast: Up 5.4% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Down 5.1% Today

Micron Technology Inc. ($MU) Stock Forecast: Down 7.0% Today

Prime Medicine Price History

02.03.2026 - PRME Stock was down 7.8%

• PRME stock experienced a significant 7.3% decline today, reaching an intraday low of $3.36 with reduced trading volume.
• The bearish movement could be attributed to market reactions following the news of the stock price drop, despite analysts maintaining a "Moderate Buy" consensus rating with a target price of $7.38.
• The upcoming pivotal year in 2026 for Prime Medicine's clinical ambitions, focusing on broader application of its gene-editing technology, might have raised concerns among investors about the company's ability to meet key milestones.
• The manufacturing breakthrough by Avaí Bio in regenerative medicine, addressing a critical hurdle in scaling production of living therapeutics, could have indirectly impacted PRME's stock performance as investors assess competitive dynamics in the sector.

31.02.2026 - PRME Stock was up 5.7%

• PRME stock experienced a 7.3% decline, reaching an intraday low of $3.36 with reduced trading volume.
• Despite the drop, analysts maintain a "Moderate Buy" consensus rating with an average target price of $7.38.
• Institutional investors like Alphabet, ARK, State Street, Vanguard, and Farallon have increased their stakes in the company.
• The decline in stock price could be attributed to profit-taking after a previous bullish run, as investors reassess the company's progress in transitioning its gene-editing technology and upcoming regulatory filings.

30.02.2026 - PRME Stock was down 5.2%

• PRME stock price dropped by 7.3% to $3.36, hitting an intraday low with lower trading volume, indicating increased selling pressure.
• Despite the decline, analysts maintain a "Moderate Buy" consensus rating with an average target price of $7.38, suggesting potential recovery in the future.
• Institutional investors like Alphabet, ARK, State Street, Vanguard, and Farallon have recently increased their stakes in the company, showing confidence in PRME's long-term prospects.
• The bearish movement could be attributed to profit-taking by some investors after a period of growth, coupled with general market volatility affecting biotech stocks.

24.02.2026 - PRME Stock was down 5.7%

• PRME reported a Q4 loss and missed revenue estimates, leading to a negative sentiment among investors and analysts.
• The stock slipped following the Q4 updates, indicating potential concerns about the company's financial performance and future prospects.
• The disappointing financial results may have eroded investor confidence in PRME, causing the bearish movement in the stock price today.

08.04.2026 - PRME Stock was down 0.2%

• Today's decline in PRME stock could be attributed to various factors:
• The Q1 2026 net loss exceeding expectations might have sparked worries among investors regarding the company's financial stability and operational longevity.
• Despite positive regulatory filings and anticipated clinical data progress in its pipeline programs, the market could have been underwhelmed by the absence of significant revenue-generating milestones in the immediate future.
• While the hiring of a new CFO could be seen as a positive move for the company's leadership, it might have introduced an element of uncertainty affecting investor sentiment.
• Overall, today's market sentiment towards PRME appears to have been swayed more by immediate financial performance concerns rather than the future promise of its gene-editing technologies.

13.03.2026 - PRME Stock was up 5.2%

• A recent downgrade to a "Strong Sell" rating appears to have initially caused a 6.4% decline in PRME's stock price.
• Despite the downgrade, the stock quickly recovered, indicating that some investors may have perceived the dip as a buying opportunity.
• Valuation metrics suggest that PRME is currently undervalued based on its forward PS ratio, potentially attracting value investors and contributing to the positive resurgence.
• Today's market movement for PRME reflects a combination of analyst assessments, valuation metrics, and investor actions, illustrating the ever-changing dynamics of stock prices in response to various influences.

07.04.2026 - PRME Stock was down 5.5%

• A rating shift from "strong sell" to "sell" by a prominent financial organization likely influenced the downward movement of PRME stock.
• Disclosures made to the SEC possibly unveiled worrisome details or future prospects, prompting a negative reaction from investors and subsequent stock depreciation.
• Despite significant institutional ownership and its cutting-edge Prime Editing technology, a change in market sentiment due to recent events has led to today's bearish trend for PRME.

07.04.2026 - PRME Stock was down 9.6%

• The bearish movement in PRME stock today could be attributed to several factors:
• Despite reporting a narrower net loss and a cash runway into 2027, investors might have been disappointed by the lack of significant revenue generation in the recent financial results.
• The downgrade of PRME from a "strong sell" to a "sell" rating by an industry analyst could have influenced market sentiment negatively, leading to increased selling pressure on the stock.
• The focus on regulatory filings for PM577 and PM647 in 2026, with clinical data expected in 2027, might have raised concerns among investors about the timeline and success of these programs, leading to a cautious approach towards the stock.
• The overall market sentiment towards biotechnology companies or the healthcare sector as a whole might have been bearish today, impacting PRME along with other similar stocks in the industry.

17.03.2026 - PRME Stock was up 5.7%

• PRME stock saw a notable uptrend following the announcement of Svetlana Makhni as the new Chief Financial Officer.
• Investors reacted favorably to Makhni's extensive background in biotech and healthcare finance, showing trust in her financial oversight abilities for the upcoming clinical trials.
• Makhni's appointment is viewed as pivotal for Prime Medicine's financial strategies, investor communications, and corporate expansion, setting the stage for future growth and medical progress.
• CEO Allan Reine stepping down from the financial officer position, ensuring clear financial and operational leadership separation, reinforced the market's optimism about PRME's future outlook.

29.03.2026 - PRME Stock was down 5.1%

• PRME's third-quarter results suffered wider losses and lower revenues compared to analyst expectations, causing a negative stock movement.
• In the previous quarter, PRME underperformed financially, but saw a positive stock movement due to non-operating income from investments.
• The uncertainty around the upcoming annual shareholder meeting and board elections may have contributed to the bearish market sentiment.
• The continuous poor financial performance and revenue misses are likely undermining investor trust in PRME, leading to the downtrend in the stock price.

11.02.2026 - PRME Stock was down 9.0%

• Concerns may have arisen in the market regarding PRME's shift towards liver diseases, potentially impacting views on diversification and market prospects.
• Investors might be exercising caution despite positive mentions by LifeSci Capital, as PRME is well-funded until 2027, hinting at a longer timeline for generating revenue.
• The CEO's positive statements on potential FDA policy changes reducing costs for rare disease treatments may have been overlooked due to profit-taking or market uncertainties, contributing to the stock's bearish movement.

11.04.2026 - PRME Stock was up 5.9%

• Despite reporting a Q1 loss and missing revenue estimates, Prime Medicine (PRME) experienced a bullish market movement today.
• The bullish trend could be attributed to the company's strategic initiatives, such as appointing new executives, initiating equity offerings, and prioritizing its liver disease programs.
• Analysts forecasting significant revenue growth and a higher price target for PRME might have also contributed to the positive market sentiment.
• Investors seem optimistic about Prime Medicine's gene-editing pipeline progress, promising preclinical data, and ongoing regulatory efforts, leading to the bullish movement in the stock.